Actinium Pharmaceuticals, Inc. income statement ATNM

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Actinium Pharmaceuticals, Inc. reported revenue of $90,000, up 11.1% from the year before. It recorded a net loss of $33.9 million. The operating loss came to $36.2 million, an operating margin of -40274.4%. Diluted earnings per share were -$1.09. Across the 4 fiscal years shown, revenue shrank from $1.1 million in fiscal 2021 to $90,000 in fiscal 2025, about 57.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	—	0 +11.1%	—	0 -92.1%	1 -10.0%	1	—	—	—	—	—
Cost of revenue	—	—	—	—	—	1	—	—	—	—	—
Gross profit	—	—	—	—	—	0	—	—	—	—	—
Research and development	18 -33.3%	21 -29.7%	30 -22.3%	39 +67.1%	23 +28.3%	18 +12.1%	16 -2.8%	17 -3.2%	17 -3.5%	18 -0.6%	18 +32.0%
Selling, general and administrative	7 -56.6%	15 +26.0%	12 -9.4%	13 +11.1%	12 +48.6%	8 +28.0%	6 +14.2%	6 -18.0%	7 -26.7%	9 +1.9%	9 -20.0%
Operating income	10 +121.6%	-36 +13.9%	-42 +18.9%	-52 -52.2%	-34 -36.6%	-25 -11.5%	-22 -1.5%	-22 +7.4%	-24 +11.5%	-27 -0.2%	-27 -8.1%
Net income	11 +127.6%	-34 +11.4%	-38 +21.7%	-49 -47.9%	-33 -33.3%	-25 -11.5%	-22 -1.4%	-22 +7.4%	-24 +11.1%	-27 -9.4%	-24 -15.7%
Basic EPS	0.36 +127.5%	-1.09 +14.2%	-1.27 +30.6%	-1.83 -33.6%	-1.37	—	—	—	—	—	—
Diluted EPS	0.36 +127.5%	-1.09 +14.2%	-1.27 +30.6%	-1.83 -33.6%	-1.37	—	—	—	—	—	—
Weighted average shares, basic	31 +0.3%	31 +3.7%	30 +13.0%	27 +10.2%	24	—	—	—	—	—	—
Weighted average shares, diluted	31 +0.3%	31 +3.7%	30 +13.0%	27 +10.2%	24	—	—	—	—	—	—
Other measures
Depreciation and amortization	0	0	—	—	—	—	—	—	—	—	0 +45.0%
EBITDA	10	-36	—	—	—	—	—	—	—	—	-27 -8.0%
Interest coverage	—	—	—	—	—	—	—	—	—	—	-5,361.99x
Margins
Gross margin	—	—	—	—	—	21.33%	—	—	—	—	—
Operating margin	—	-40,274.44%	—	-64,098.77%	-3,311.07%	-2,182.17%	—	—	—	—	—
Profit margin	—	-37,652.22%	—	-60,269.14%	-3,205.53%	-2,165.56%	—	—	—	—	—
EBITDA margin	—	-40,082.22%	—	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ATNM (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1388320
Former names: Cactus Ventures, Inc. (until Mar 29, 2013)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.